10,656 Shares in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Purchased by New York Life Investment Management LLC

New York Life Investment Management LLC purchased a new stake in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) in the 4th quarter, Holdings Channel reports. The fund purchased 10,656 shares of the biopharmaceutical company’s stock, valued at approximately $763,000.

A number of other hedge funds have also recently bought and sold shares of ITCI. Xponance Inc. boosted its holdings in shares of Intra-Cellular Therapies by 3.0% in the 4th quarter. Xponance Inc. now owns 5,676 shares of the biopharmaceutical company’s stock valued at $407,000 after buying an additional 163 shares during the last quarter. Regal Investment Advisors LLC lifted its stake in Intra-Cellular Therapies by 1.4% in the third quarter. Regal Investment Advisors LLC now owns 13,610 shares of the biopharmaceutical company’s stock valued at $709,000 after acquiring an additional 186 shares during the last quarter. State Board of Administration of Florida Retirement System grew its position in shares of Intra-Cellular Therapies by 0.8% in the 3rd quarter. State Board of Administration of Florida Retirement System now owns 26,796 shares of the biopharmaceutical company’s stock valued at $1,396,000 after acquiring an additional 200 shares during the period. Bailard Inc. increased its stake in shares of Intra-Cellular Therapies by 1.2% during the 4th quarter. Bailard Inc. now owns 17,080 shares of the biopharmaceutical company’s stock worth $1,223,000 after purchasing an additional 200 shares during the last quarter. Finally, Signaturefd LLC raised its holdings in shares of Intra-Cellular Therapies by 85.7% in the 4th quarter. Signaturefd LLC now owns 518 shares of the biopharmaceutical company’s stock valued at $37,000 after purchasing an additional 239 shares during the period. 92.33% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of research firms recently commented on ITCI. The Goldman Sachs Group lifted their price target on Intra-Cellular Therapies from $67.00 to $77.00 and gave the stock a “neutral” rating in a report on Wednesday, April 17th. Bank of America boosted their target price on Intra-Cellular Therapies from $82.00 to $91.00 and gave the stock a “buy” rating in a report on Wednesday, April 17th. Needham & Company LLC reaffirmed a “buy” rating and set a $90.00 price target on shares of Intra-Cellular Therapies in a report on Tuesday. Robert W. Baird lifted their price objective on shares of Intra-Cellular Therapies from $83.00 to $103.00 and gave the stock an “outperform” rating in a research report on Wednesday, April 17th. Finally, Canaccord Genuity Group increased their price objective on shares of Intra-Cellular Therapies from $100.00 to $107.00 and gave the company a “buy” rating in a research report on Tuesday, April 23rd. Two research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $90.17.

Insider Buying and Selling

In related news, CFO Lawrence J. Hineline sold 13,337 shares of the company’s stock in a transaction dated Monday, February 26th. The shares were sold at an average price of $69.43, for a total transaction of $925,987.91. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. In other Intra-Cellular Therapies news, CFO Lawrence J. Hineline sold 13,337 shares of the business’s stock in a transaction that occurred on Monday, February 26th. The shares were sold at an average price of $69.43, for a total transaction of $925,987.91. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, EVP Suresh K. Durgam sold 6,450 shares of the stock in a transaction dated Thursday, March 7th. The stock was sold at an average price of $66.56, for a total transaction of $429,312.00. Following the completion of the transaction, the executive vice president now directly owns 16,170 shares of the company’s stock, valued at approximately $1,076,275.20. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 168,487 shares of company stock worth $11,364,950. Company insiders own 3.40% of the company’s stock.

Intra-Cellular Therapies Stock Down 5.9 %

NASDAQ ITCI opened at $67.00 on Thursday. The firm has a 50-day moving average price of $69.03 and a two-hundred day moving average price of $65.86. Intra-Cellular Therapies, Inc. has a 12-month low of $45.50 and a 12-month high of $84.89. The company has a market capitalization of $6.49 billion, a P/E ratio of -45.89 and a beta of 1.01.

Intra-Cellular Therapies (NASDAQ:ITCI) last issued its quarterly earnings results on Tuesday, May 7th. The biopharmaceutical company reported ($0.16) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.31) by $0.15. The business had revenue of $144.90 million for the quarter, compared to the consensus estimate of $141.41 million. Intra-Cellular Therapies had a negative return on equity of 23.02% and a negative net margin of 30.08%. The firm’s quarterly revenue was up 52.0% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($0.46) earnings per share. Equities analysts expect that Intra-Cellular Therapies, Inc. will post -0.59 EPS for the current year.

Intra-Cellular Therapies Profile

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.